questionsmedicales.fr
Acides nucléiques, nucléotides et nucléosides
Nucléotides
Ribonucléotides
Nucléotides uridyliques
Uridine diphosphate
Uridine diphosphate : Questions médicales fréquentes
Termes MeSH sélectionnés :
Attention Deficit Disorder with Hyperactivity
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Uridine diphosphate : Questions médicales les plus fréquentes",
"headline": "Uridine diphosphate : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Uridine diphosphate : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-22",
"dateModified": "2025-04-18",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Uridine diphosphate"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Nucléotides uridyliques",
"url": "https://questionsmedicales.fr/mesh/D014500",
"about": {
"@type": "MedicalCondition",
"name": "Nucléotides uridyliques",
"code": {
"@type": "MedicalCode",
"code": "D014500",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.919"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Uridine diphosphate ose",
"alternateName": "Uridine Diphosphate Sugars",
"url": "https://questionsmedicales.fr/mesh/D014539",
"about": {
"@type": "MedicalCondition",
"name": "Uridine diphosphate ose",
"code": {
"@type": "MedicalCode",
"code": "D014539",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.919.600.677"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Uridine diphosphate N-acétylgalactosamine",
"alternateName": "Uridine Diphosphate N-Acetylgalactosamine",
"url": "https://questionsmedicales.fr/mesh/D014536",
"about": {
"@type": "MedicalCondition",
"name": "Uridine diphosphate N-acétylgalactosamine",
"code": {
"@type": "MedicalCode",
"code": "D014536",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.919.600.677.100"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Uridine diphosphate N-acétylglucosamine",
"alternateName": "Uridine Diphosphate N-Acetylglucosamine",
"url": "https://questionsmedicales.fr/mesh/D014537",
"about": {
"@type": "MedicalCondition",
"name": "Uridine diphosphate N-acétylglucosamine",
"code": {
"@type": "MedicalCode",
"code": "D014537",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.919.600.677.120"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Acide uridine diphosphate N-acétylmuramique",
"alternateName": "Uridine Diphosphate N-Acetylmuramic Acid",
"url": "https://questionsmedicales.fr/mesh/D014538",
"about": {
"@type": "MedicalCondition",
"name": "Acide uridine diphosphate N-acétylmuramique",
"code": {
"@type": "MedicalCode",
"code": "D014538",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.919.600.677.150"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Uridine diphosphate galactose",
"alternateName": "Uridine Diphosphate Galactose",
"url": "https://questionsmedicales.fr/mesh/D014531",
"about": {
"@type": "MedicalCondition",
"name": "Uridine diphosphate galactose",
"code": {
"@type": "MedicalCode",
"code": "D014531",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.919.600.677.300"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Uridine diphosphate glucose",
"alternateName": "Uridine Diphosphate Glucose",
"url": "https://questionsmedicales.fr/mesh/D014532",
"about": {
"@type": "MedicalCondition",
"name": "Uridine diphosphate glucose",
"code": {
"@type": "MedicalCode",
"code": "D014532",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.919.600.677.350"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Acide uridine diphosphate glucuronique",
"alternateName": "Uridine Diphosphate Glucuronic Acid",
"url": "https://questionsmedicales.fr/mesh/D014535",
"about": {
"@type": "MedicalCondition",
"name": "Acide uridine diphosphate glucuronique",
"code": {
"@type": "MedicalCode",
"code": "D014535",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.919.600.677.375"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Uridine diphosphate xylose",
"alternateName": "Uridine Diphosphate Xylose",
"url": "https://questionsmedicales.fr/mesh/D014540",
"about": {
"@type": "MedicalCondition",
"name": "Uridine diphosphate xylose",
"code": {
"@type": "MedicalCode",
"code": "D014540",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.919.600.677.800"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "Uridine diphosphate",
"alternateName": "Uridine Diphosphate",
"code": {
"@type": "MedicalCode",
"code": "D014530",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Takayuki Matsumoto",
"url": "https://questionsmedicales.fr/author/Takayuki%20Matsumoto",
"affiliation": {
"@type": "Organization",
"name": "Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Shinagawa-ku, Tokyo 142-8501, Japan. Electronic address: t-matsu@hoshi.ac.jp."
}
},
{
"@type": "Person",
"name": "Kumiko Taguchi",
"url": "https://questionsmedicales.fr/author/Kumiko%20Taguchi",
"affiliation": {
"@type": "Organization",
"name": "Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Shinagawa-ku, Tokyo 142-8501, Japan."
}
},
{
"@type": "Person",
"name": "Tsuneo Kobayashi",
"url": "https://questionsmedicales.fr/author/Tsuneo%20Kobayashi",
"affiliation": {
"@type": "Organization",
"name": "Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Shinagawa-ku, Tokyo 142-8501, Japan. Electronic address: tkoba@hoshi.ac.jp."
}
},
{
"@type": "Person",
"name": "Rafal Jonczyk",
"url": "https://questionsmedicales.fr/author/Rafal%20Jonczyk",
"affiliation": {
"@type": "Organization",
"name": "Biotechnology of Natural Products, Technische Universität München, 85354 Freising, Germany."
}
},
{
"@type": "Person",
"name": "Thomas Hoffmann",
"url": "https://questionsmedicales.fr/author/Thomas%20Hoffmann",
"affiliation": {
"@type": "Organization",
"name": "Biotechnology of Natural Products, Technische Universität München, 85354 Freising, Germany."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Attachment in adolescents with attention deficit hyperactivity disorder and oppositional defiant disorder.",
"datePublished": "2022-06-30",
"url": "https://questionsmedicales.fr/article/36342984",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.12740/PP/OnlineFirst/130366"
}
},
{
"@type": "ScholarlyArticle",
"name": "Prevalence of Personality Disorders in Adults With Attention Deficit Hyperactivity Disorder (ADHD).",
"datePublished": "2023-03-16",
"url": "https://questionsmedicales.fr/article/36927130",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/10870547231161531"
}
},
{
"@type": "ScholarlyArticle",
"name": "Pharmacotherapy of Attention-Deficit/Hyperactivity Disorder in Individuals with Autism Spectrum Disorder.",
"datePublished": "2022-05-11",
"url": "https://questionsmedicales.fr/article/35697395",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.chc.2022.03.012"
}
},
{
"@type": "ScholarlyArticle",
"name": "Pragmatic Deficits in Attention Deficit/Hyperactivity Disorder: Systematic Review and Meta-Analysis.",
"datePublished": "2023-03-28",
"url": "https://questionsmedicales.fr/article/36975307",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/10870547231161534"
}
},
{
"@type": "ScholarlyArticle",
"name": "Oculomotor deficits in attention deficit hyperactivity disorder: a systematic review and meta-analysis.",
"datePublished": "2022-10-24",
"url": "https://questionsmedicales.fr/article/36280758",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41433-022-02284-z"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides nucléiques, nucléotides et nucléosides",
"item": "https://questionsmedicales.fr/mesh/D009706"
},
{
"@type": "ListItem",
"position": 3,
"name": "Nucléotides",
"item": "https://questionsmedicales.fr/mesh/D009711"
},
{
"@type": "ListItem",
"position": 4,
"name": "Ribonucléotides",
"item": "https://questionsmedicales.fr/mesh/D012265"
},
{
"@type": "ListItem",
"position": 5,
"name": "Nucléotides uridyliques",
"item": "https://questionsmedicales.fr/mesh/D014500"
},
{
"@type": "ListItem",
"position": 6,
"name": "Uridine diphosphate",
"item": "https://questionsmedicales.fr/mesh/D014530"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Uridine diphosphate - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Uridine diphosphate",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-03",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Uridine diphosphate",
"description": "Comment diagnostiquer une carence en UDP ?\nQuels tests sont utilisés pour évaluer l'UDP ?\nL'UDP peut-il être mesuré dans le sang ?\nQuels symptômes indiquent un problème d'UDP ?\nY a-t-il des marqueurs spécifiques pour l'UDP ?",
"url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=Attention+Deficit+Disorder+with+Hyperactivity&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Uridine diphosphate",
"description": "Quels sont les symptômes d'une carence en UDP ?\nL'UDP affecte-t-il le système nerveux ?\nDes douleurs musculaires peuvent-elles être liées à l'UDP ?\nL'UDP influence-t-il l'humeur ?\nY a-t-il des signes cutanés associés à l'UDP ?",
"url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=Attention+Deficit+Disorder+with+Hyperactivity&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Uridine diphosphate",
"description": "Comment prévenir une carence en UDP ?\nLes suppléments sont-ils nécessaires pour l'UDP ?\nY a-t-il des groupes à risque pour l'UDP ?\nLes habitudes de vie influencent-elles l'UDP ?\nDes conseils nutritionnels existent-ils pour l'UDP ?",
"url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=Attention+Deficit+Disorder+with+Hyperactivity&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Uridine diphosphate",
"description": "Comment traiter une carence en UDP ?\nLes médicaments peuvent-ils aider à l'UDP ?\nY a-t-il des thérapies alternatives pour l'UDP ?\nLes changements alimentaires sont-ils efficaces ?\nDes traitements spécifiques existent-ils pour l'UDP ?",
"url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=Attention+Deficit+Disorder+with+Hyperactivity&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Uridine diphosphate",
"description": "Quelles complications peuvent survenir avec une carence en UDP ?\nL'UDP peut-il affecter le développement ?\nDes maladies chroniques sont-elles liées à l'UDP ?\nL'UDP est-il impliqué dans des maladies héréditaires ?\nDes troubles immunitaires peuvent-ils être liés à l'UDP ?",
"url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=Attention+Deficit+Disorder+with+Hyperactivity&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Uridine diphosphate",
"description": "Quels sont les facteurs de risque pour l'UDP ?\nL'âge influence-t-il les niveaux d'UDP ?\nLe stress peut-il affecter l'UDP ?\nLes maladies génétiques influencent-elles l'UDP ?\nLes habitudes alimentaires jouent-elles un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D014530?mesh_terms=Attention+Deficit+Disorder+with+Hyperactivity&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une carence en UDP ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests biochimiques mesurant les niveaux d'UDP dans les cellules peuvent être effectués."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'UDP ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests enzymatiques et chromatographiques sont couramment utilisés pour évaluer l'UDP."
}
},
{
"@type": "Question",
"name": "L'UDP peut-il être mesuré dans le sang ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'UDP est généralement mesuré dans les tissus plutôt que dans le sang en raison de sa faible concentration."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un problème d'UDP ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme la fatigue, des troubles neurologiques ou des anomalies métaboliques peuvent survenir."
}
},
{
"@type": "Question",
"name": "Y a-t-il des marqueurs spécifiques pour l'UDP ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de marqueurs spécifiques, mais des niveaux d'enzymes peuvent indiquer des anomalies."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une carence en UDP ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, faiblesse musculaire et troubles cognitifs."
}
},
{
"@type": "Question",
"name": "L'UDP affecte-t-il le système nerveux ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une carence en UDP peut entraîner des troubles neurologiques et cognitifs."
}
},
{
"@type": "Question",
"name": "Des douleurs musculaires peuvent-elles être liées à l'UDP ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs musculaires peuvent survenir en raison d'un métabolisme énergétique altéré."
}
},
{
"@type": "Question",
"name": "L'UDP influence-t-il l'humeur ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une carence en UDP peut affecter l'humeur et entraîner des troubles de l'humeur."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes cutanés associés à l'UDP ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anomalies cutanées peuvent apparaître, mais elles sont moins fréquentes."
}
},
{
"@type": "Question",
"name": "Comment prévenir une carence en UDP ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée riche en acides nucléiques peut aider à prévenir une carence."
}
},
{
"@type": "Question",
"name": "Les suppléments sont-ils nécessaires pour l'UDP ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les suppléments peuvent être bénéfiques, surtout en cas de régime alimentaire pauvre."
}
},
{
"@type": "Question",
"name": "Y a-t-il des groupes à risque pour l'UDP ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes ayant des troubles métaboliques ou des régimes restrictifs sont à risque."
}
},
{
"@type": "Question",
"name": "Les habitudes de vie influencent-elles l'UDP ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des habitudes de vie saines, comme l'exercice, peuvent soutenir le métabolisme de l'UDP."
}
},
{
"@type": "Question",
"name": "Des conseils nutritionnels existent-ils pour l'UDP ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, consulter un nutritionniste peut aider à élaborer un plan alimentaire adapté."
}
},
{
"@type": "Question",
"name": "Comment traiter une carence en UDP ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement peut inclure des suppléments d'uridine et des modifications alimentaires."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils aider à l'UDP ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains médicaments peuvent améliorer le métabolisme de l'UDP, mais nécessitent une prescription."
}
},
{
"@type": "Question",
"name": "Y a-t-il des thérapies alternatives pour l'UDP ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies comme la nutrition ciblée peuvent être bénéfiques, mais nécessitent des études."
}
},
{
"@type": "Question",
"name": "Les changements alimentaires sont-ils efficaces ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en acides nucléiques peut aider à augmenter les niveaux d'UDP."
}
},
{
"@type": "Question",
"name": "Des traitements spécifiques existent-ils pour l'UDP ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de traitements spécifiques approuvés pour les troubles liés à l'UDP."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une carence en UDP ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications neurologiques et métaboliques peuvent survenir si non traitées."
}
},
{
"@type": "Question",
"name": "L'UDP peut-il affecter le développement ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une carence en UDP peut nuire au développement cognitif et physique chez les enfants."
}
},
{
"@type": "Question",
"name": "Des maladies chroniques sont-elles liées à l'UDP ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines maladies métaboliques chroniques peuvent être exacerbées par une carence en UDP."
}
},
{
"@type": "Question",
"name": "L'UDP est-il impliqué dans des maladies héréditaires ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles héréditaires du métabolisme peuvent affecter les niveaux d'UDP."
}
},
{
"@type": "Question",
"name": "Des troubles immunitaires peuvent-ils être liés à l'UDP ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une carence en UDP peut affaiblir le système immunitaire, augmentant le risque d'infections."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour l'UDP ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les régimes alimentaires pauvres, les maladies métaboliques et le stress sont des facteurs de risque."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il les niveaux d'UDP ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les niveaux d'UDP peuvent diminuer avec l'âge, augmentant le risque de carence."
}
},
{
"@type": "Question",
"name": "Le stress peut-il affecter l'UDP ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut perturber le métabolisme de l'UDP et entraîner des carences."
}
},
{
"@type": "Question",
"name": "Les maladies génétiques influencent-elles l'UDP ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines maladies génétiques peuvent affecter la synthèse et l'utilisation de l'UDP."
}
},
{
"@type": "Question",
"name": "Les habitudes alimentaires jouent-elles un rôle ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation déséquilibrée peut augmenter le risque de carence en UDP."
}
}
]
}
]
}
To assess attachment styles among adolescents (13-16 years) with ADHD or ADHD and oppositional defiant disorders (ODD)....
The Parents and Peers Attachment (IPPA) and the Parent Bonding Questionnaire (PBI) were used in three groups of teenagers raised in biological families: (1) ADHD/ODD group (n = 40), (2) ADHD group (n ...
Parental attachment styles in the area of "Trust", "Communication" and "Alienation" (IPPA), and "Care" and "Control" (PBI) in the ADHD/ODD group differ significantly compared to the control group. Tee...
The attachment style is significantly different in adolescents diagnosed with ADHD and ODD than in adolescents with only ADHD. In the ADHD/ODD group and the ADHD group, unlike in the group of adolesce...
To estimate the prevalence of PDs according to Millon's evolution-based model among adult ADHD outpatients....
Cross-sectional study of consecutive patients referred to an adult ADHD clinic. PDs were evaluated with Millon Clinical Multiaxial Inventory-III (MCMI-III)....
One-hundred-eighty-one participants had valid MCMI-III, of whom147 were diagnosed with ADHD. Mean age: 32.97, SD:11.56, females: 74 (50.3%). Among the 147 participants with ADHD, 29 (19.7%) did not me...
Particular personality profiles were more common with different ADHD subtypes. Given the developmental origins of PD, further research may help identify possible links with childhood difficulties....
Attention-deficit/hyperactivity disorder (ADHD) is the most frequent comorbid disorder that is observed at a higher rate and with greater morbidity in higher intellectually functioning populations wit...
While poorer pragmatic language skills have been found in attention-deficit/hyperactivity disorder (ADHD) populations, there has been no conclusive evidence of this. We aimed to conduct a meta-analysi...
Studies were identified using the search terms ((attention deficit) OR (adhd)) AND (pragmatics), and those studies were screened and reviewed for inclusion criteria, descriptive information, and outco...
A total of 14 studies (5,772 participants) met the criteria for quantitative synthesis. Meta-analysis indicated that ADHD populations exhibited significantly poorer pragmatic language skills than TD p...
It is suggested that pragmatic language skills may deserve greater surveillance considering the importance of pragmatic language in socio-emotional development, daily life, and academic success....
There is equivocal evidence on the presence of oculomotor deficits among children with attention deficit hyperactivity disorder (ADHD), which can be an additional challenge in this population, especia...
Emerging evidence implicate the gut microbiota as a potential susceptibility factor in attention-deficit hyperactivity disorder (ADHD), a common multifactorial neurodevelopmental condition. However, l...
Comorbidities are common in children with epilepsy, with nearly half of the patients having at least one comorbidity. Attention deficit hyperactivity disorder (ADHD) is a psychiatric disorder characte...
Rates of cannabis use have been rising in the US due to the increasing legalization/decriminalization of cannabis products for medical and recreational use. Individuals with attention-deficit hyperact...
People with attention deficit and hyperactivity disorder (ADHD) present attentional and emotional deficits and show paradoxical qualities such as hyperfocus. Previous studies have reported errors, slo...
Thirty French children and teenagers, 15 with ADHD and 15 neurotypical (NT), underwent a saccadic eye movement task. We conducted conventional analysis (movement duration, precision, velocity, RT) and...
Saccade duration and velocity failed to differentiate the two groups, whereas amplitude was higher in ADHD than in NT participants. Saccade RT and variability were higher in ADHD than in NT participan...
ADHD disrupts two mechanisms of action: it reduces the gain of the decision signal, thus explaining slowness and variability; it quickens the decision process of early responses at the origin of short...
These premises and their interconnections explain previous observations and support the striatal-frontal wiring of ADHD, thus explaining ADHD complexity in its negative and positive manifestations....
The association between attention-deficit/hyperactivity disorder (ADHD) and schizophrenia has received increased attention; however, evidence on the association between psychiatric comorbidities and s...
To investigate the risk of being diagnosed with schizophrenia in children and adolescents with ADHD considering the presence of psychiatric comorbidity....
This was a population-based, retrospective cohort study using the Health Insurance Review and Assessment claims database from January 1, 2007, to December 31, 2019. Participants were children and adol...
The presence of psychiatric comorbidity was assessed from diagnosis records within 1 year before ADHD diagnosis. Comorbidities were further categorized according to the number of comorbidities and spe...
Cox proportional hazard models were used to estimate hazard ratios (HRs) and 95% CIs, examining the association between psychiatric comorbidities and the risk of being diagnosed with schizophrenia. Fu...
A total of 211 705 patients with newly diagnosed ADHD were included. A total of 157 272 patients (74.3%) were male, and the age of 5 to 9 years showed the highest distribution (115 081 patients [54.4%...
In this retrospective cohort study involving children and adolescents with ADHD, the presence of psychiatric comorbidity in patients with ADHD was associated with an increased risk of being diagnosed ...